Xp11 Translocation Renal Cell Carcinoma: Delayed but Massive and Lethal Metastases of a Chemotherapy-Associated Secondary Malignancy
Authors:
- Soroush Rais-BahramiSoroush Rais-Bahrami
- Joseph J. DrabickJDJoseph J. Drabick
- Angelo M. De MarzoAMAngelo M. De Marzo
- Jessica HicksJHJessica Hicks
- Clement HoCHClement Ho
- Alan E. CaroeACAlan E. Caroe
- Pedram ArganiPAPedram Argani
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET InhibitionCancer Research, 2007
- Pediatric Renal Cell CarcinomaAmerican Journal of Clinical Pathology, 2006
- The Evolving Story of Renal Translocation CarcinomasAmerican Journal of Clinical Pathology, 2006
- Translocation Carcinomas of the Kidney After Chemotherapy in ChildhoodJournal of Clinical Oncology, 2006
- Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinomaCancer, 2004
- Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene FusionsAmerican Journal of Surgical Pathology, 2003
- Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part SarcomaThe American Journal of Pathology, 2001
- Two New Cases of Papillary Renal Cell Carcinoma with t(X;1)(p11;q21) in FemalesCancer Genetics and Cytogenetics, 1999
- Translocation (X;1) reveals metastasis 31 years after renal cell carcinomaCancer Genetics and Cytogenetics, 1998